Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes

Diabetes Care

Volumn 35, Issue 1, 2012, Pages 4-11

  Dushay, Jody ^a   Gao, Chuanyun ^a   Gopalakrishnan, Gosala S ^a   Crawley, Meghan ^a   Mitten, Emilie K ^a   Wilker, Elissa ^a   Mullington, Janet ^a   Maratos Flier, Eleftheria ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; PLACEBO;

ADULT; AGED; ARTICLE; BLOATING; BODY MASS; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG WITHDRAWAL; ERUCTATION; FATIGUE; FEMALE; HEARTBURN; HUMAN; HYPOGLYCEMIA; INJECTION SITE IRRITATION; MENSTRUATION DISORDER; NAUSEA; OBESITY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SATIETY; SIDE EFFECT; UNITED STATES; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; NAUSEA; OBESITY; PEPTIDES; RECEPTORS, GLUCAGON; VENOMS; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 84859046364     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-0931     Document Type: Article

References (24)

1. Glant M, Raz I. Present and future: pharmacologic treatment of obesity. J Obes 2011;2011:636181
2. Foster GD, Wyatt HR, Hill JO, et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med 2010;153:147-157
3. Shai I, Schwarzfuchs D, Henkin Y, et al.; Dietary Intervention Randomized Controlled Trial (DIRECT) Group. Weight loss with alow-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008;359:229-241 (Pubitemid 352008438)
4. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009;360:859-873
5. Barte JCM, ter Bogt NCW, Bogers RP, et al. Maintenance of weight loss after lifestyle interventions for overweight and obesity, a systematic review. Obes Rev 2010;11:899-906
6. Anderson JW, Konz EC, Frederich RC, Wood CL. Long-term weight-loss maintenance: ameta-analysis of US studies. Am J Clin Nutr 2001;74:579-584 (Pubitemid 33015142)
7. O'Brien PE. Bariatric surgery: mechanisms, indications and outcomes. J Gastroenterol Hepatol 2010;25:1358-1365
8. Tong J, Sandoval DA. Is the GLP-1 system a viable therapeutic target for weight reduction? Rev Endocr Metab Disord 2011; 12:187-195
9. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001;86:4382-4389 (Pubitemid 32848563)
10. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-830 (Pubitemid 34233752)
11. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD; Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-2635 (Pubitemid 39441462)
12. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-1100 (Pubitemid 40616618)
13. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-1091 (Pubitemid 40616617)
14. Buse JB, Rosenstock J, Sesti G, et al.; LEAD 6Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:1606-1616
15. Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010;33:1173-1175
16. Astrup A, Rössner S, Van Gaal L, et al.; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-1616
17. Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care 2010;33:1759-1765
18. Blonde L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006;8:436-447 (Pubitemid 44349236)
19. Rosenbaum M, Leibel RL. Adaptive thermogenesis inhumans. Int J Obes 2010;34(Suppl. 1):S47-S55
20. Leibel RL, Rosenbaum M, Hirsch J. Changes inenergy expenditure resulting from altered body weight. N Engl J Med 1995;322:621-628
21. Pereira MA, Swain J, Goldfine AB, Rifai N, Ludwig DS. Effects of alow-glycemic load diet on resting energy expenditure and heart disease risk factors during weight loss. JAMA 2004;292:2482-2490 (Pubitemid 39552673)
22. Yamamoto H, Kishi T, Lee CE, et al. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 2003;23:2939-2946 (Pubitemid 36418630)
23. Shalev A, Holst JJ, Keller U. Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man. Eur J Clin Invest 1997;27:10-16 (Pubitemid 27065167)
24. Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther. 19December 2010 [Epub ahead of print]